Market Closed -
Nasdaq Stockholm
09:30:00 28/06/2024 pm IST
|
5-day change
|
1st Jan Change
|
0.426
SEK
|
-1.84%
|
|
+6.50%
|
-2.52%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
90.48
|
177.2
|
108.9
|
142.8
|
100.7
|
98.13
|
-
|
-
|
Enterprise Value (EV)
1 |
87.81
|
177.2
|
90.48
|
77.63
|
49.94
|
55.13
|
58.13
|
98.13
|
P/E ratio
|
-2.25
x
|
-7.09
x
|
-
|
-2.21
x
|
-1.68
x
|
-2.13
x
|
-2.13
x
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
204
x
|
-
|
9.08
x
|
3.86
x
|
2.34
x
|
1.68
x
|
1.28
x
|
1
x
|
EV / Revenue
|
198
x
|
-
|
7.54
x
|
2.1
x
|
1.16
x
|
0.94
x
|
0.76
x
|
1
x
|
EV / EBITDA
|
-5.07
x
|
-
|
-3.48
x
|
-5.45
x
|
-3.51
x
|
-15.8
x
|
22.4
x
|
5.91
x
|
EV / FCF
|
-21.8
x
|
-
|
-3.21
x
|
-4.64
x
|
-
|
-6.89
x
|
-19.4
x
|
-
|
FCF Yield
|
-4.59%
|
-
|
-31.2%
|
-21.5%
|
-
|
-14.5%
|
-5.16%
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
75,712
|
75,712
|
1,14,613
|
2,30,361
|
2,30,361
|
2,30,361
|
-
|
-
|
Reference price
2 |
1.195
|
2.340
|
0.9500
|
0.6200
|
0.4370
|
0.4260
|
0.4260
|
0.4260
|
Announcement Date
|
21/02/20
|
19/02/21
|
07/04/22
|
23/02/23
|
22/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.443
|
-
|
12
|
36.99
|
43.04
|
58.4
|
76.6
|
98
|
EBITDA
1 |
-17.34
|
-
|
-25.99
|
-14.25
|
-14.25
|
-3.5
|
2.6
|
16.6
|
EBIT
1 |
-20.74
|
-
|
-50.57
|
-59.3
|
-59.78
|
-47.7
|
-41.7
|
-3.2
|
Operating Margin
|
-4,680.81%
|
-
|
-421.58%
|
-160.34%
|
-138.91%
|
-81.68%
|
-54.44%
|
-3.27%
|
Earnings before Tax (EBT)
1 |
-20.74
|
-
|
-
|
-58.97
|
-59.3
|
-46
|
-42
|
-
|
Net income
1 |
-20.74
|
-24.05
|
-
|
-58.97
|
-59.3
|
-46
|
-42
|
-
|
Net margin
|
-4,680.81%
|
-
|
-
|
-159.45%
|
-137.78%
|
-78.77%
|
-54.83%
|
-
|
EPS
2 |
-0.5300
|
-0.3300
|
-
|
-0.2800
|
-0.2600
|
-0.2000
|
-0.2000
|
-
|
Free Cash Flow
1 |
-4.032
|
-
|
-28.21
|
-16.72
|
-
|
-8
|
-3
|
-
|
FCF margin
|
-910.16%
|
-
|
-235.13%
|
-45.2%
|
-
|
-13.7%
|
-3.92%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21/02/20
|
19/02/21
|
07/04/22
|
23/02/23
|
22/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
7.77
|
6.349
|
10.4
|
12.47
|
11.05
|
11.78
|
10.7
|
9.511
|
12.8
|
13.6
|
15.2
|
16.8
|
17.1
|
EBITDA
1 |
-
|
-10.62
|
-10.94
|
-5.99
|
-
|
-
|
-
|
-
|
-
|
-
|
-2.1
|
-1.1
|
-0.5
|
-0.2
|
EBIT
1 |
-
|
-15.7
|
-16.01
|
-11.07
|
-16.53
|
-13.67
|
-15.48
|
-13.26
|
-17.36
|
-10.77
|
-13.2
|
-12.2
|
-11.6
|
-11.3
|
Operating Margin
|
-
|
-201.99%
|
-252.23%
|
-106.41%
|
-132.53%
|
-123.68%
|
-131.51%
|
-123.97%
|
-182.57%
|
-84.14%
|
-97.06%
|
-80.26%
|
-69.05%
|
-66.08%
|
Earnings before Tax (EBT)
|
-20.25
|
-15.7
|
-16.02
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-15.49
|
-15.9
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-199.32%
|
-250.4%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
07/04/22
|
29/04/22
|
17/08/22
|
27/10/22
|
23/02/23
|
03/05/23
|
23/08/23
|
02/11/23
|
22/02/24
|
03/05/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
2.66
|
-
|
18.4
|
65.2
|
50.7
|
43
|
40
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-4.03
|
-
|
-28.2
|
-16.7
|
-
|
-8
|
-3
|
-
|
ROE (net income / shareholders' equity)
|
-30.7%
|
-
|
-37.1%
|
-26.8%
|
-30.7%
|
-33%
|
-44%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.25
|
-
|
-
|
3.02
|
-
|
2
|
2
|
-
|
Capex / Sales
|
55.3%
|
-
|
-
|
8.18%
|
-
|
3.42%
|
2.61%
|
-
|
Announcement Date
|
21/02/20
|
19/02/21
|
07/04/22
|
23/02/23
|
22/02/24
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -2.52% | 92.59L | | +19.41% | 4.55TCr | | -8.62% | 3.85TCr | | +38.65% | 3.81TCr | | +26.95% | 3.07TCr | | -13.50% | 2.6TCr | | +10.74% | 2.59TCr | | +44.87% | 1.41TCr | | +34.36% | 1.27TCr | | -7.14% | 1.13TCr |
Other Biotechnology & Medical Research
|